






# Summary of Experimental Intervention Study and Clinical Efficacy Studies on of Kinostat® on Cataracts in Galactosemic and Diabetic Dogs



**Therapeutic  
Vision, Inc.**

**PRESERVING VISION AND HEARING FOR YOU  
AND YOUR PETS**


# Intervention Study: Kinostat preserves vision after administration at the early stages of cataract development in galactosemic dogs.



Kador PF, Betts D, Wyman M, Blessing K, Randazzo J. Effects of topical administration of an aldose reductase inhibitor on cataract formation in dogs fed a diet high in galactose. Am J Vet Res 2006;67:1783-7.



# Pre-FDA Proof of Concept Clinical Trial: Kinostat®\* prevents the onset and progression of sugar cataract in a 12-month masked 2 center placebo-controlled study in diabetic dogs



Kador PF, Webb TR, Bras D, Ketrang K, Wyman M. Topical KINOSTAT ameliorates the clinical development and progression of cataracts in dogs with diabetes mellitus. Vet Ophthalmol 2010;13:363-8.



A randomized multicenter double masked placebo-controlled clinical trial (1/3 placebo) of topical Kinostat<sup>®</sup> was conducted at 11 centers across the United States.



Conducted under Protocol TV-2 FDA INAD I-011785






**Kinostat® is the first clinically validated preventive for vision loss for diabetic dogs that significantly reduced the onset and progression of cataracts in newly diagnosed diabetic dogs.**

In a 9-month Modified Intent to Treat 11-Center, Masked, Placebo-Controlled Efficacy Study under Protocol TV-2 under FDA INAD I-011785, Kinostat®-treated dogs were:



- **85% less likely to develop cataracts**
- **84% less likely to develop dry eye**

**179 dogs were recruited (33% placebo) and 146 completed the 9 month study**

- Dogs dropping out before Month 2 for any reason were counted as drug failures equivalent to stage 2 cataracts
- Dogs dropping out after Month 1 were not counted because of protocol noncompliance.
- 14 dogs who died or were euthanized for reasons unrelated to the study were removed from the analysis even though they did not develop stage 2




Retinal features are still clear after 8 years of Kinostat® treatment below



**In a subsequent Compassionate Use Trial of 92 FDA study dogs cataracts were prevented for up to 10 years**

Without Kinostat® retinal features are not evident through a cataractous lens





\* Dogs without cataracts after the FDA trial received Kinostat® for the rest of their lives with 6-month exams



# Compassionate Use Study: Long-term treatment of Kinostat<sup>®</sup> prevents sugar cataracts up to 10 years

**In a subsequent Compassionate Use Trial, 92 FDA study dogs with no Grade 2 cataracts received Kinostat for the rest of their lives with lens changes monitored with 6-month examinations**

**Retinal features are still clear after 8 years of Kinostat<sup>®</sup> treatment below**



**Without Kinostat<sup>®</sup> retinal features are not evident through a cataractous lens**

